Key Points
- Director Robert Denton sold 3,922 shares of COPT Defense Properties on May 26 at an average price of $32.38, reducing his stake by about 50.8% to 3,803 shares.
- Q1 earnings missed expectations: the company posted EPS of $0.34 versus the $0.68 consensus, though revenue came in above estimates at $200.64 million and was up 6.8% year over year.
- The company maintained a quarterly dividend of $0.32 per share, equal to an annualized yield of 3.9%, while analysts currently rate the stock a consensus Moderate Buy with a $34.50 target price.
COPT Defense Properties (NYSE:CDP - Get Free Report) Director Robert Denton sold 3,922 shares of the business's stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $32.38, for a total transaction of $126,994.36. Following the sale, the director directly owned 3,803 shares in the company, valued at approximately $123,141.14. The trade was a 50.77% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.
COPT Defense Properties Stock Performance
NYSE CDP opened at $32.49 on Friday. The firm's fifty day moving average price is $31.73 and its two-hundred day moving average price is $30.80. The stock has a market cap of $3.68 billion, a PE ratio of 23.54 and a beta of 0.80. COPT Defense Properties has a fifty-two week low of $26.91 and a fifty-two week high of $33.33. The company has a debt-to-equity ratio of 1.63, a quick ratio of 2.85 and a current ratio of 2.85.
COPT Defense Properties (NYSE:CDP - Get Free Report) last posted its earnings results on Monday, April 27th. The company reported $0.34 earnings per share for the quarter, missing analysts' consensus estimates of $0.68 by ($0.34). The company had revenue of $200.64 million for the quarter, compared to the consensus estimate of $185.10 million. COPT Defense Properties had a return on equity of 10.02% and a net margin of 20.10%.The business's quarterly revenue was up 6.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.65 EPS. COPT Defense Properties has set its FY 2026 guidance at 2.730-2.790 EPS and its Q2 2026 guidance at 0.680-0.700 EPS. On average, equities analysts expect that COPT Defense Properties will post 2.78 EPS for the current fiscal year.
COPT Defense Properties Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Tuesday, June 30th will be paid a $0.32 dividend. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $1.28 annualized dividend and a dividend yield of 3.9%. COPT Defense Properties's dividend payout ratio is currently 92.75%.
Wall Street Analysts Forecast Growth
Several research analysts have recently issued reports on CDP shares. Truist Financial upped their price objective on COPT Defense Properties from $31.00 to $33.00 and gave the company a "hold" rating in a research note on Tuesday, March 3rd. JPMorgan Chase & Co. upped their price objective on COPT Defense Properties from $33.00 to $34.00 and gave the company a "neutral" rating in a research note on Friday, May 15th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $37.00 price objective on shares of COPT Defense Properties in a research note on Wednesday, April 29th. Weiss Ratings raised COPT Defense Properties from a "buy (b-)" rating to a "buy (b)" rating in a research note on Tuesday, April 21st. Finally, Evercore reaffirmed an "outperform" rating and issued a $38.00 price objective on shares of COPT Defense Properties in a research note on Tuesday, April 28th. Five equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $34.50.
Read Our Latest Report on COPT Defense Properties
Hedge Funds Weigh In On COPT Defense Properties
Hedge funds and other institutional investors have recently bought and sold shares of the company. EverSource Wealth Advisors LLC boosted its holdings in COPT Defense Properties by 16.3% during the 1st quarter. EverSource Wealth Advisors LLC now owns 2,424 shares of the company's stock worth $74,000 after acquiring an additional 339 shares during the last quarter. California State Teachers Retirement System boosted its holdings in COPT Defense Properties by 0.4% during the 2nd quarter. California State Teachers Retirement System now owns 104,190 shares of the company's stock worth $2,874,000 after acquiring an additional 457 shares during the last quarter. Arizona State Retirement System boosted its holdings in COPT Defense Properties by 1.4% during the 3rd quarter. Arizona State Retirement System now owns 33,402 shares of the company's stock worth $971,000 after acquiring an additional 459 shares during the last quarter. State of Michigan Retirement System boosted its holdings in COPT Defense Properties by 1.9% during the 1st quarter. State of Michigan Retirement System now owns 27,213 shares of the company's stock worth $833,000 after acquiring an additional 500 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its holdings in COPT Defense Properties by 2.5% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 20,780 shares of the company's stock worth $588,000 after acquiring an additional 513 shares during the last quarter.
COPT Defense Properties Company Profile
(
Get Free Report)
COPT Defense Properties (NYSE: CDP) is a real estate investment trust organized to own, lease and manage healthcare and life science facilities serving the United States federal government, with a particular focus on Department of Defense and Veterans Affairs tenants. The company was formed in 2016 through a spin-off from Corporate Office Properties Trust, enabling it to concentrate exclusively on medical office buildings and specialized research facilities situated on or near military and federal research campuses.
The company's portfolio comprises purpose-built, Class A medical office and outpatient specialty clinics, as well as life science laboratories.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
